Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G. Eckert C, et al. Among authors: borkhardt a. Eur J Cancer. 2013 Apr;49(6):1346-55. doi: 10.1016/j.ejca.2012.11.010. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265714
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J. Schlieben S, et al. Among authors: borkhardt a. Leukemia. 1996 Jun;10(6):957-63. Leukemia. 1996. PMID: 8667652 Clinical Trial.
Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group.
Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A. Borkhardt A, et al. Blood. 1997 Jul 15;90(2):571-7. Blood. 1997. PMID: 9226156 Free article.
Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.
Langer T, Metzler M, Reinhardt D, Viehmann S, Borkhardt A, Reichel M, Stanulla M, Schrappe M, Creutzig U, Ritter J, Leis T, Jacobs U, Harbott J, Beck JD, Rascher W, Repp R. Langer T, et al. Among authors: borkhardt a. Genes Chromosomes Cancer. 2003 Apr;36(4):393-401. doi: 10.1002/gcc.10167. Genes Chromosomes Cancer. 2003. PMID: 12619163
Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia.
Metzler M, Strissel PL, Strick R, Niemeyer C, Roettgers S, Borkhardt A, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Reinhardt D, Creutzig U, Beck JD, Rascher W, Repp R, Langer T. Metzler M, et al. Among authors: borkhardt a. Genes Chromosomes Cancer. 2004 Nov;41(3):291-6. doi: 10.1002/gcc.20083. Genes Chromosomes Cancer. 2004. PMID: 15334554
NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms.
Kracht T, Schrappe M, Strehl S, Reiter A, Elsner HA, Trka J, Cario G, Viehmann S, Harbott J, Borkhardt A, Metzler M, Langer T, Repp R, Marschalek R, Welte K, Haas OA, Stanulla M. Kracht T, et al. Among authors: borkhardt a. Haematologica. 2004 Dec;89(12):1492-7. Haematologica. 2004. PMID: 15590400
481 results